Exacerbated CSF abnormalities in younger patients with Alzheimer's disease

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 486-491

  Dumurgier, Julien ^a   Gabelle, Audrey ^b   Vercruysse, Olivier ^c,d   Bombois, Stéphanie ^c   Laplanche, Jean Louis ^a   Peoc'h, Katell ^a   Schraen, Susanna ^c,d   Sablonnière, Bernard ^c,d   Pasquier, Florence ^c   Touchon, Jacques ^b   Lehmann, Sylvain ^b   Hugon, Jacques ^a,e   Paquet, Claire ^a,e  

^a HÔPITAL FERNAND WIDAL   (France)

^b UNIV MONTPELLIER   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

^e INSTITUT DU FER À MOULIN   (France)

Author keywords

Age factor; Alzheimer's disease; CSF biomarkers; Epidemiology

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGE DISTRIBUTION; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ABNORMALITY; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SEX;

AGE FACTORS; AGE OF ONSET; AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; ROC CURVE; TAU PROTEINS;

EID: 84876328138     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.01.023     Document Type: Article

References (42)

1. Andreasen N., et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 1999, 56:673-680.
2. Blennow K., et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
3. Bouwman F.H., et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol. Aging 2009, 30:1895-1901.
4. Bradford A., et al. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis. Assoc. Disord. 2009, 23:306-314.
5. Choo I.H., et al. Relationship of amyloid-beta burden with age-at-onset in Alzheimer disease. Am. J. Geriatr. Psychiatry 2011, 19:627-634.
6. de Waal H., et al. Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. Neurobiol. Aging 2012, 33(1008):e25-e31.
7. Duyckaerts C., et al. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118:5-36.
8. Fagan A.M., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
9. Farrer L.A., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
10. Fratiglioni L., et al. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997, 48:132-138.
11. Gabelle A., et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J. Alzheimers Dis. 2011, 26:553-563.
12. Gatz M., et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 2006, 63:168-174.
13. Glodzik-Sobanska L., et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol. Aging 2009, 30:672-681.
14. Gold G., et al. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol. 2000, 99:579-582. (discussion 583-4).
15. Helmer C., et al. Dementia in subjects aged 75years or over within the PAQUID cohort: prevalence and burden by severity. Dement. Geriatr. Cogn. Disord. 2006, 22:87-94.
16. Hirtz D., et al. How common are the "common" neurologic disorders?. Neurology 2007, 68:326-337.
17. Ho G.J., et al. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport 2002, 13:1825-1828.
18. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010, 120:287-296.
19. Janicki S.C., Schupf N. Hormonal influences on cognition and risk for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2010, 10:359-366.
20. Jellinger K.A., Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008, 115:427-436.
21. Jorm A.F., Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998, 51:728-733.
22. Kester M.I., et al. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J. Alzheimers Dis. 2009, 16:601-607.
23. Koedam E.L., et al. Early- versus late-onset Alzheimer's disease: more than age alone. J. Alzheimers Dis. 2010, 19:1401-1408.
24. Kok E., et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 2009, 65:650-657.
25. Kukull W.A., et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 2002, 59:1737-1746.
26. Lewis H., et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol. Appl. Neurobiol. 2006, 32:103-118.
27. Marshall G.A., et al. Early-onset Alzheimer's disease is associated with greater pathologic burden. J. Geriatr. Psychiatry Neurol. 2007, 20:29-33.
28. Mattsson N., et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012, 78:468-476.
29. McKhann G., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
30. Middleton L.E., et al. Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology 2011, 77:1737-1744.
31. Perneczky R., et al. Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology 2010, 75:137-142.
32. Perret-Liaudet A., et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin. Chem. 2012, 58:787-789.
33. Perrin R.J., et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
34. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
35. Rabinovici G.D., et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010, 133:512-528.
36. Savva G.M., et al. Age, neuropathology, and dementia. N. Engl. J. Med. 2009, 360:2302-2309.
37. Seppala T.T., et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012, 78:1568-1575.
38. Shinagawa S., et al. Frequency and clinical characteristics of early-onset dementia in consecutive patients in a memory clinic. Dement. Geriatr. Cogn. Disord. 2007, 24:42-47.
39. Strozyk D., et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
40. Tapiola T., et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009, 66:382-389.
41. Valcour V.G., et al. The detection of dementia in the primary care setting. Arch. Intern. Med. 2000, 160:2964-2968.
42. van der Vlies A.E., et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009, 72:1056-1061.